MENU

Can Xtant Medical Holdings (XTNT) Stock Reach $1.03?

a manufacturer of surgical products

A.I.Advisor
published price charts
A.I.Advisor
Nov 10, 2026

Can Xtant Medical Holdings (XTNT) Stock Reach $1.03?

Key Takeaways

  • The central target used here is $1.03, the arithmetic mean of four verified analyst price targets, rounded from roughly $1.025.
  • Analyst targets range from a low of $0.60 to a high of $1.50, a wide spread that reflects genuine disagreement about this small-cap's outlook.
  • With the latest verified share price near $0.28, reaching $1.03 would require an upside of roughly 268%, a very large move.
  • The strongest supporting factors are the Dilon/HEMOBLAST distribution agreement and a materially expanded sales force, though growth has yet to show up in results.
  • The biggest risks are declining revenue, compressed gross margins, a swing to net losses, and a tight liquidity position.
  • For more context on this company, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • You can also explore Trending AI Robots to see AI-driven strategies across thousands of tickers.

Analyst Price Targets and Consensus View

Xtant Medical Holdings, Inc. (XTNT) is a small-cap medical technology company selling orthobiologics, spine implants, and regenerative products used in spine and orthopedic surgery. Four current analyst price targets were reviewed: BTIG's Ryan Zimmerman at $1.00 (maintained May 2026), Craig-Hallum's Chase Knickerbocker at $0.60 (cut from $1.20 on Aug. 12, 2026), Maxim Group at $1.50 (Aug. 28, 2026), and Lucid Capital Markets' Alex Nowark at $1.00 (initiated Sept. 2, 2026). The range spans $0.60 to $1.50, and the arithmetic mean is about $1.025, rounded to $1.03 for this analysis.

Every reviewed rating is a Buy or equivalent, but the spread between the low and high targets is unusually wide. The more cautious targets reflect the company's sharply lower second-quarter results and reduced guidance, while the higher targets weight the potential of the HEMOBLAST Bellows distribution deal and the expanded commercial team. The mean is a statistical summary, not a guarantee or a published consensus.

Current Market Position and Path Toward the Target

At the latest verified close near $0.28, XTNT sits near the lower end of its 52-week range of roughly $0.27 to $0.95. Reaching $1.03 would require a gain of about 268%, a very large move for any company, and especially demanding for a business whose revenue is currently contracting.

The reported fundamentals are weak. Second-quarter 2026 revenue fell to $23.0 million from $35.4 million a year earlier, gross margin declined to 57.9% from 68.6%, and the company swung to a net loss of $9.4 million from net income of $3.6 million. Full-year 2026 revenue guidance was lowered to $99 million to $103 million. A durable path toward the target would likely require stabilizing revenue, recovering margins, and a return toward positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).

What Could Support a Move Toward the Target

  • The exclusive U.S. distribution agreement with Dilon Technologies for HEMOBLAST Bellows adds a hemostatic biologic and expands the company's addressable market; management targets more than $1 million per month in gross transactional volume.
  • The commercial team has expanded materially, with the addition of roughly 17 Dilon sales reps and managers, supporting cross-selling across the biologics portfolio.
  • New product traction, including the Trivium Shaped launch and the Cortera Spinal Fixation System, partially offset biologics weakness in the latest quarter.
  • Gross margins remain above 57%, indicating the underlying product economics are intact even as scale has declined.

What Could Prevent the Target From Being Reached

  • Revenue is declining rather than growing, with legacy orthobiologics and the amnio (wound-care) line underperforming.
  • Persistent amnio reimbursement pressure and advanced wound-care headwinds are expected to continue through the back half of 2026.
  • Margin compression and negative adjusted EBITDA raise questions about the timeline for returning to profitability.
  • Liquidity is constrained: cash fell to $9.9 million at June 30, 2026, with roughly $23 million in debt, leaving limited room to absorb further operating losses.
  • The wide analyst target range itself signals low visibility into the company's near-term trajectory.

Technical Levels and Market Structure

The 52-week range of roughly $0.27 to $0.95 shows the stock has lost substantial ground, and the current price near $0.28 is close to the low end of that range. The $0.27 area is a key support level to monitor, while any recovery toward $0.40 to $0.45 and then the prior high near $0.95 would represent progressively larger resistance zones well below the $1.03 target. As a low-priced, thinly traded micro-cap, XTNT can experience sharp percentage moves in either direction, so technical levels should be treated cautiously.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ. The most important upcoming items are the next quarterly earnings report and any revision to full-year guidance, as well as evidence on whether HEMOBLAST transaction volume reaches the company's $1 million-per-month target and whether the integrated sales force drives sequential biologics growth. Analyst revisions, gross-margin trends, cash balances, and amnio reimbursement developments will also be key to whether the gap between the current price and the $1.03 target narrows.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap such as XTNT, tools that track shifting trends can help traders screen opportunities and monitor positions more efficiently than manual review. Traders looking for an automated edge can explore these signals to stay ahead of rapidly changing market conditions.

Final Assessment

The $1.03 central target is the rounded arithmetic mean of four analyst price targets ranging from $0.60 to $1.50. At a recent price near $0.28, that target implies roughly 268% upside, an exceptionally large move. The bull case rests on the HEMOBLAST distribution agreement, a much larger sales organization, and the possibility of stabilizing margins, while the bear case is grounded in falling revenue, margin compression, net losses, and tight liquidity. The unusually wide analyst range underscores how little certainty surrounds the stock's near-term path. Whether XTNT can ultimately reach $1.03 depends first on delivering the sequential revenue recovery management has guided toward, and investors should watch the next earnings report and guidance closely. This article makes no prediction or recommendation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

XTNT and Stocks

Correlation & Price change

A.I.dvisor tells us that XTNT and STRRP have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XTNT and STRRP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTNT
1D Price
Change %
XTNT100%
-1.31%
STRRP - XTNT
31%
Poorly correlated
N/A
CVRX - XTNT
26%
Poorly correlated
-3.60%
ACRS - XTNT
25%
Poorly correlated
-2.00%
MBOT - XTNT
24%
Poorly correlated
-4.98%
OM - XTNT
24%
Poorly correlated
-3.37%
More

Groups containing XTNT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTNT
1D Price
Change %
XTNT100%
-1.31%
Health Services
category (238 stocks)
7%
Poorly correlated
-1.01%
Medical/Nursing Services
category (138 stocks)
7%
Poorly correlated
-1.10%
Can Xtant Medical Holdings (XTNT) Stock Reach $1.03?